Advanced Oncotherapy - Director/PDMR Shareholding
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Director/PDMR Shareholdings
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that, on
Furthermore, on
Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.
- ENDS -
|
Advanced Oncotherapy plc |
|
|
Dr |
Tel: +44 (0) 20 3617 8728 |
|
|
|
|
|
|
|
Allenby Capital Limited (Nomad and Joint Broker) |
|
|
|
Tel: +44 (0) 20 3328 5656 |
|
|
|
|
SI Capital Ltd (Joint Broker) |
|
|
|
Tel: +44 (0) 1483 413 500 |
|
|
Tel: +44 (0) 20 3871 4066 |
|
|
|
|
|
|
|
|
|
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
|
1 |
Details of the person discharging managerial responsibilities |
|
|
a) |
Name |
Dr.
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Non-Executive Director |
|
b)
|
Initial notification /Amendment |
Initial notification |
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Advanced Oncotherapy plc |
|
b) |
LEI |
213800LUDHZOG3YT6C82 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a)
|
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109 |
|
b) |
Nature of the transaction |
Purchase of shares
|
|
c) |
Price(s) and volume(s) |
Price(s)- Volume (s)- 80,000
|
|
d) |
Aggregated information - Aggregated volume - Price |
N/A
|
|
e) |
Date of the transaction |
|
|
f) |
Place of the transaction |
London Stock Exchange |
|
1 |
Details of the person discharging managerial responsibilities |
|
|
a) |
Name |
Prof.
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Director & Executive Chairman of ADAM SA |
|
b)
|
Initial notification /Amendment |
Initial notification |
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Advanced Oncotherapy plc |
|
b) |
LEI |
213800LUDHZOG3YT6C82 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a)
|
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109 |
|
b) |
Nature of the transaction |
Purchase of shares
|
|
c) |
Price(s) and volume(s) |
Price(s)- Volume (s)- 70,000
|
|
d) |
Aggregated information - Aggregated volume - Price |
N/A
|
|
e) |
Date of the transaction |
|
|
f) |
Place of the transaction |
London Stock Exchange |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE